Psychedelics and Existing Psychiatric Care: What Participants Should Know

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: People who are in ongoing psychiatric care — on medications, working with a therapist or psychiatrist, or managing a diagnosed mental health condition — and who are considering accessing psilocybin through Oregon’s or Colorado’s licensed programs, a clinical trial, or another context.

The short answer

If you are currently in psychiatric care — taking psychiatric medications, working with a prescriber, or managing a condition like depression, bipolar disorder, PTSD, or psychosis — there are important clinical and legal questions to navigate before a psilocybin session. The licensed state programs have formal eligibility criteria, but those criteria are narrow minimums, not a comprehensive medical safety review. The responsibility to flag your full medical and psychiatric picture falls largely on you. A licensed facilitator in Oregon is not required to be a medical professional and may not recognize clinically relevant risks that your history presents.

What Oregon’s program formally screens for

Oregon’s licensed psilocybin program disqualifies clients who meet any of three formal criteria during the preparation session:

Current ideation of harm to self or others
Lithium use within the past 30 days
A history of diagnosis or treatment for active psychosis at any time

The Client Information Form asks about these three items as yes/no questions. If you answer no to all three, you are formally eligible under the program’s screening requirements. That is the program’s floor, not a clinical clearance.

The informed consent document advises — but does not require — that clients with prescription medications or medical or mental health conditions consult a clinical provider before participating. This is the extent of the program’s clinical oversight obligation before a session.

Medications: what matters and why

Lithium: a hard stop under Oregon rules

Lithium use within the past 30 days is an absolute disqualifier under Oregon’s licensed program and cannot be waived. This reflects a genuine safety concern: naturalistic survey data suggests that co-administration of psilocybin with lithium may increase the risk of seizure. If you take lithium for bipolar disorder or otherwise, you cannot participate in Oregon’s program within 30 days of any lithium dose. Stopping lithium is a significant medical decision that requires supervision — it is not something to do without your prescribing physician’s guidance.

SSRIs and SNRIs: a more complex picture

Most clinical trials of psilocybin have historically required participants to discontinue SSRIs and SNRIs before receiving psilocybin. The concern has been twofold: that serotonergic antidepressants may downregulate the 5-HT2A receptors that psilocybin acts on, potentially blunting the experience and therapeutic effects, and that combining serotonergic agents theoretically risks serotonin syndrome.

The clinical evidence on both concerns has evolved. Several recent studies — including an open-label trial of psilocybin in treatment-resistant depression patients remaining on SSRIs (Goodwin et al., 2023) — found that concurrent SSRI use did not eliminate psilocybin’s effects and showed a generally favorable safety profile. A 2025 scoping review of published data on antidepressant and psychedelic co-administration found that the combination was not reliably associated with serotonin toxicity and may not significantly blunt therapeutic outcomes.

At the same time, the evidence also shows that antidepressant discontinuation itself carries risks. Abrupt or rapid tapering of SSRIs and SNRIs can cause discontinuation symptoms — physical symptoms, mood instability, worsening depression — and has been associated with increased depression scores and, in some case reports, clinical deterioration in the period leading up to a psilocybin session.

The upshot is that neither continuing your antidepressant nor stopping it before a session is a risk-free default. This is a decision that warrants a conversation with your prescribing physician, who knows your history and can weigh the clinical tradeoffs specific to your situation. Oregon’s program does not formally screen for SSRI or SNRI use. Facilitators are not required to assess or manage medication interactions.

MAOIs: do not combine

Monoamine oxidase inhibitors have been excluded from virtually all psilocybin clinical trials due to the theoretical risk of dangerous serotonin-related reactions. The existing evidence base on psilocybin does not include populations taking MAOIs, and the interaction risk is not well characterized. If you take an MAOI (phenelzine, tranylcypromine, selegiline, or others), do not combine it with psilocybin without explicit medical guidance. This applies regardless of whether the session is in a licensed program or otherwise.

Antipsychotics

Antipsychotics — particularly dopamine receptor antagonists — may blunt or block psilocybin’s effects, since the two act on overlapping neural systems. Someone using antipsychotics is also likely to have a psychiatric history that raises the question of the formal psychosis exclusion criterion. This is a class of medication where a conversation with your prescribing provider is essential before any decision about participation.

Other psychiatric medications

Many other medications affect the serotonergic system or interact with psilocybin in ways that are not yet well characterized — tricyclic antidepressants, some mood stabilizers, certain antihistamines, and triptans among them. Oregon’s facilitation model requires that facilitators encourage clients with health conditions to consult a medical provider. It does not require that they do so, and it does not require facilitators to check or assess your full medication list for interactions.

Psychiatric conditions: what the program screens for and what it does not

History of psychosis

The Oregon program formally disqualifies anyone with a history of diagnosis or treatment for active psychosis. This is a threshold question — it does not distinguish between a brief, resolved episode and ongoing psychotic illness. If you have ever been diagnosed with or treated for active psychosis, that triggers the disqualification under program rules, and a facilitator who learns of this must decline services.

This does not mean that psilocybin is necessarily unsafe for everyone with any psychosis-related history — the evidence base is limited and the research is ongoing. But within the Oregon licensed program as it currently operates, a history of active psychosis treatment is a formal bar.

Bipolar disorder

Bipolar disorder is not a formal disqualifier under Oregon’s program in the way that a psychosis history is. But clinical trial research on psilocybin has consistently excluded people with bipolar I disorder due to the risk of psilocybin triggering manic episodes or psychotic episodes in that population. Survey data of people with bipolar disorder who have self-administered psilocybin outside clinical contexts documents significant rates of adverse outcomes, including new or worsening manic symptoms. This is a clinically significant risk that the Oregon program’s screening process is not designed to catch.

If you have a bipolar disorder diagnosis, particularly bipolar I, discussing a planned psilocybin session with your psychiatrist before proceeding is not optional from a safety standpoint, even though it is not required by the program.

Cardiovascular conditions

Psilocybin increases heart rate and blood pressure during sessions. The Informed Consent document discloses this. People with cardiovascular conditions — particularly uncontrolled hypertension, a history of arrhythmia, or significant cardiac disease — face heightened risk from these physiological effects. These conditions are not formal disqualifiers under Oregon’s program. A facilitator without medical training is unlikely to recognize their significance. Consulting your cardiologist or primary care provider before a session is appropriate if you have a relevant cardiac history.

What your ongoing care team needs to know

Your prescribing physician and therapist may or may not know about your intention to access psilocybin services. In a licensed Oregon or Colorado setting, participation itself is legal under state law and not something that requires your therapist’s or psychiatrist’s permission. But for reasons of your own safety, your ongoing providers should know:

What you are planning to do and where
What medications you are taking and whether any tapering or discontinuation is under consideration
Whether you have conditions or a history that the licensed program’s screening does not catch

Involving your existing care team also matters for continuity after a session. Psilocybin experiences can be psychologically intense and may bring up significant material. If your ongoing therapist or prescriber knows a session occurred, they can support the integration process in a clinically informed way.

What facilitators can and cannot do

A licensed Oregon psilocybin facilitator is trained in facilitation — how to hold space, how to support someone through a session, when to call emergency services. A facilitator is not required to be a physician, a nurse, or a therapist. Oregon’s rules explicitly prohibit facilitators from practicing another licensed profession while providing psilocybin services, which means that even a facilitator who holds a therapy license cannot provide therapy during a session.

Facilitators may not assess or manage drug interactions. They are not positioned to evaluate whether your specific medication history creates risk. The program’s expectation is that clients disclose relevant information and, if they have health conditions, have consulted a medical provider. A facilitator who becomes aware of a serious safety concern may decline to proceed — and retains the right to do so for any reason — but the clinical evaluation of your medication profile is not part of a facilitator’s role.

When public information may be enough

If your question is how existing psychiatric care intersects with psilocybin access and what the programs formally screen for, this article covers that. For what the informed consent process requires you to acknowledge, What disclosures and consent forms should I receive before a session? covers the specific documents and what each one means. For what happens during a session and what support is available, What does the participant intake and session process actually look like? addresses that. For clinical trial participation as an alternative that provides closer medical oversight, Clinical trials vs. legal access programs: what’s the difference? covers that pathway.

When you should speak with a lawyer

Speaking with a lawyer is not the primary resource for medication questions — that is your prescribing physician. But you should speak with a lawyer if:

You have a professional license as a healthcare provider and want to understand how participation affects your licensing obligations
Something went wrong during a session that you believe was related to inadequate screening or a failure to identify a known risk, and you are considering a legal claim
You have a healthcare directive, guardianship, or other legal arrangement that intersects with your ability to make independent decisions about participation

You might also want to read

This article is public legal education, not legal advice. If your situation involves medical decisions, speak with your prescribing physician. If your situation involves legal risk, speak with a lawyer who practices in this area.